With a market size of more than US$9bn, China is Asia-Pacific’s largest in-vitro diagnostics (IVD) market. EIU Healthcare expects China’s IVD market size to expand by more than 10% each year from 2017-2022.
From strong growth in molecular diagnostics and next-generation sequencing, to overall test prices getting squeezed by new reimbursement schemes, find out where the fastest-growing areas in IVD are, and factors that influence the demand of different IVD tests in China.
Here is EIU Healthcare’s forecast on the fastest-growing areas in China’s IVD market:
- Immunodiagnostics used in the critical care setting is the fastest-growing immunodiagnostics area in centralised diagnostics (CDx). What are the top 3 fastest-growing immunodiagnostics areas in CDx and its growth drivers?
- Connected blood glucose testing in hospitals is the fastest-growing area in China’s point-of-care (POC) diagnostics market. What are the top 3 fastest-growing areas in POC diagnostics and its growth drivers?
- Genomics is the fastest-growing area in China’s molecular diagnostics (MDx) market. What are the top 3 fastest-growing areas in MDx and its growth drivers?
- Special stains is the fastest-growing area in China’s tissue diagnostics (TDx) market. What are the top 3 fastest-growing areas in TDx and its growth drivers?
For more insights, speak to us on how EIU Healthcare’s IVD Gateway can deliver accurate, comprehensive data and forecasts to help you understand your business’s present market position and future market opportunities.
Sign up to receive future infographics and publications from EIU Healthcare.